Omada Health (NASDAQ:OMDA) CEO Sells $3,595,472.40 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 230,479 shares of Omada Health stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.60, for a total transaction of $3,595,472.40. Following the transaction, the chief executive officer directly owned 126,644 shares in the company, valued at $1,975,646.40. This trade represents a 64.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Omada Health Trading Down 3.9%

OMDA stock traded down $0.63 during midday trading on Wednesday, hitting $15.50. The company had a trading volume of 865,768 shares, compared to its average volume of 910,452. The stock has a market cap of $897.57 million and a price-to-earnings ratio of -62.00. The stock’s 50 day moving average price is $17.22 and its 200 day moving average price is $20.04. Omada Health, Inc. has a 52 week low of $14.14 and a 52 week high of $28.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Omada Health in the third quarter valued at approximately $38,000. Raymond James Financial Inc. purchased a new position in Omada Health during the second quarter worth approximately $32,000. Bellevue Group AG grew its stake in Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after acquiring an additional 1,791 shares during the period. Rakuten Investment Management Inc. purchased a new stake in shares of Omada Health during the third quarter worth about $49,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Omada Health in the third quarter valued at approximately $82,000.

Analyst Ratings Changes

OMDA has been the topic of several recent research reports. Needham & Company LLC upped their price target on Omada Health from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Omada Health in a report on Wednesday, October 8th. Barclays cut their target price on shares of Omada Health from $29.00 to $22.00 and set an “overweight” rating for the company in a research report on Monday, January 5th. Wells Fargo & Company began coverage on Omada Health in a research report on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on Omada Health in a report on Thursday, November 13th. They set an “outperform” rating and a $27.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Omada Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.